New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
15:19 EDTNVSNovartis says subpoenaed during 2012 over marketing practices
In its 2012 annual report, filed yesterday, Novartis Pharmaceuticals disclosed that during last year it received a subpoena from the United States Attorney’s Office for the Western District of Kentucky requesting the production of documents relating to marketing practices, including remuneration of healthcare providers, in connection with certain NPC products including Tekturna and its combination products. Novartis said it is cooperating with the investigation, which is civil and criminal in nature. Novartis also disclosed that in 2012 it received a civil investigative demand from the USAO for the Southern District of New York requesting information regarding its interactions with specialty pharmacies concerning certain NPC products including Gleevec and Gilenya. NPC again said it is cooperating with the civil investigation. Novartis also said that during the fourth quarter of 2012, it learned that the U.S. government is not pursuing further informed consent issues relating to clinical trials in China related to an investigation that began in 2010. The government continues to investigate marketing practices, including marketing practices concerning Zometa, Novartis said. Additionally, Novartis' Alcon Laboratories unit was notified that the USAO for the Northern District of Texas is conducting an investigation relating to the export of Alcon products to various countries subject to U.S. trade sanctions, including Iran, and received a grand jury subpoena requesting the production of documents for a period beginning in 2005 relating to this investigation, in which Alcon is cooperating.
News For NVS From The Last 14 Days
Check below for free stories on NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
17:28 EDTNVSNovartis heart drug LCZ696 could drive shares to new highs, Barron's says
Subscribe for More Information
10:29 EDTNVSHigh option volume stocks
Subscribe for More Information
07:59 EDTNVSElbit Imaging subsidiary announces Gamida Cell completed execution of agreements
Subscribe for More Information
07:01 EDTNVSNovartis volatility expected to move on heart failure drug LCZ696 study
Subscribe for More Information
August 31, 2014
14:04 EDTNVSWorldwide Business Research to hold a conference
Subscribe for More Information
13:47 EDTNVSNovartis heart failure drug LCZ696 shows superiority to enalapril in study
Subscribe for More Information
12:50 EDTNVSEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
16:21 EDTNVSOn The Fly: Closing Wrap
Subscribe for More Information
12:23 EDTNVSNovartis drug data to be presented this weekend
Subscribe for More Information
12:18 EDTNVSOn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTNVSHigh option volume stocks
Subscribe for More Information
10:51 EDTNVSUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.
10:17 EDTNVSInnoPharma announces FDA approval of generic Dacogen
Subscribe for More Information
10:04 EDTNVSNovartis hematopoietic support for ALL patients granted orphan status
Novartis' hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor antagonist was granted orphan designation as a hematopoietic support in patients with acute lymphoblastic leukemia, or ALL, the FDA stated. Reference Link
08:46 EDTNVSNovartis has a conference call hosted by JPMorgan
JPMorgan Analyst Vosser hosts a conference call with CEO Joe Jimenez on September 5 at 8 am.
August 28, 2014
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use